School of Data Science, Fudan University, Shanghai, China.
Laiya Consulting, Inc, Shanghai, China.
JCO Precis Oncol. 2022 Aug;6:e2200046. doi: 10.1200/PO.22.00046.
Through Bayesian inference, we propose a method called BayeSize as a reference tool for investigators to assess the sample size and its associated scientific property for phase I clinical trials.
BayeSize applies the concept of effect size in dose finding, assuming that the maximum tolerated dose can be identified on the basis of an interval surrounding its true value because of statistical uncertainty. Leveraging a decision framework that involves composite hypotheses, BayeSize uses two types of priors, the fitting prior (for model fitting) and sampling prior (for data generation), to conduct sample size calculation under the constraints of statistical power and type I error.
Simulation results showed that BayeSize can provide reliable sample size estimation under the constraints of type I/II error rates.
BayeSize could facilitate phase I trial planning by providing appropriate sample size estimation. Look-up tables and R Shiny app are provided for practical applications.
通过贝叶斯推断,我们提出了一种名为 BayeSize 的方法,作为研究人员评估 I 期临床试验样本量及其相关科学属性的参考工具。
BayeSize 将效应大小的概念应用于剂量发现中,假设由于统计不确定性,可以根据其真实值周围的区间来确定最大耐受剂量。利用涉及复合假设的决策框架,BayeSize 使用两种类型的先验,拟合先验(用于模型拟合)和抽样先验(用于数据生成),在统计功效和 I 类错误率的约束下进行样本量计算。
模拟结果表明,BayeSize 可以在 I 型/II 型错误率的约束下提供可靠的样本量估计。
BayeSize 可以通过提供适当的样本量估计来促进 I 期试验计划。为了实际应用,提供了查找表和 R Shiny 应用程序。